ditiocarb has been researched along with camostat in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Emori, Y; Ichimura, M; Koide, N; Matsumura, N; Mizushima, T; Ochi, K; Shinji, T; Shirahige, A; Tanimoto, M; Tanioka, H | 1 |
2 other study(ies) available for ditiocarb and camostat
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Camostat, an oral trypsin inhibitor, reduces pancreatic fibrosis induced by repeated administration of a superoxide dismutase inhibitor in rats.
Topics: Administration, Oral; Animals; Disease Models, Animal; Ditiocarb; Drug Administration Schedule; Esters; Fibrosis; Gabexate; Guanidines; Male; Pancreas; Pancreatic Diseases; Procollagen-Proline Dioxygenase; Rats; Rats, Wistar; Severity of Illness Index; Treatment Outcome; Trypsin Inhibitors | 2005 |